ISP-001
Mucopolysaccharidosis type I (MPS I)
PreclinicalActive
Key Facts
About Immusoft
Immusoft is a private, preclinical-stage biotech based in Seattle, pioneering a novel cell therapy platform that reprograms a patient's own B cells into long-lived protein factories. Its lead program, ISP-001, targets Mucopolysaccharidosis type I (MPS I), with the goal of providing a one-time, potentially curative treatment by enabling the body to continuously produce the missing enzyme. The company's technology, if successful, could disrupt the treatment paradigm for a wide range of protein-deficient diseases, offering advantages in durability, manufacturability, and patient convenience over traditional enzyme replacement therapies or other gene therapy approaches.
View full company profileTherapeutic Areas
Other Mucopolysaccharidosis type I (MPS I) Drugs
| Drug | Company | Phase |
|---|---|---|
| RGX-111 | ReGenX Biosciences | Phase I/II |